Sun Pharma reported consolidated revenue growth of 8.7% for Q4 FY27, led by its FinTech division, which contributed 27% of the total. Operating margin held at 4.1%, a few basis points below the previous quarter as higher logistics and wage costs offset operating leverage.
On the post-results call, management said the order book now stands at $2.2 billion, equivalent to roughly 14 months of revenue, with about a third from export customers in USA and Australia. The chief financial officer described visibility as the best in five years.
The numbers
Analysts were broadly constructive. Of 18 brokerages covering the stock, 12 maintain buy ratings, with target prices implying about 27% upside. The more cautious voices pointed to a valuation premium and the execution risk inherent in a large expansion programme.
Capital expenditure guidance was raised to $2.2 billion for the fiscal year, from $161 million previously. Management said the increase reflects accelerated spending on automation and on debottlenecking existing lines, which it expects to deliver 4.1% more output without additional land.
By the numbers
Export performance was a bright spot. Shipments to USA rose 8.7%, helped by certification wins and shorter lead times from Hazira. Management said it would deepen its presence in the market by adding a local warehouse and a technical service team.
“We are building where the customers are asking us to build. That is the simplest capital-allocation rule there is.”
Expansion and capital allocation
Risks were not ignored. Executives flagged input-cost volatility, potential delays in environmental clearances for the new plant and the possibility of tougher competition from lower-priced imports. They said a pricing-pass-through mechanism covers about 60 percent of exposure.
Source: IGEN Intelligence analysis of directorate general of foreign trade data. Illustrative mock data.
Environmental, social and governance targets also featured. The company reiterated its goal to reduce emissions intensity by a third by 2030, and disclosed that 27% of electricity at its main sites now comes from renewable sources under long-term contracts.
| Segment | Revenue | YoY | Margin |
|---|---|---|---|
| FinTech (core) | $76M | +11.7% | 19.7% |
| Exports | $153M | +19.4% | 18.3% |
| Domestic retail | $486M | +10.8% | 13.8% |
| Services | $382M | +19.5% | 9.9% |
| Other | $360M | -2.7% | 10.7% |
Customers, contracts and exports
Balance-sheet metrics remain comfortable. Net debt to earnings stood at 0.8 times, and the company retired $161 million of high-cost borrowings during the quarter. Credit analysts say the improvement leaves room to fund the expansion without equity dilution.
Timeline of key events
- Results announced
Revenue up 8.7%; margin steady at 4.1%.
- Capex raised
Guidance moves to $2.2 billion to fund automation and debottlenecking.
- Supply pact signed
Multi-year agreement with Hindalco Industries at index-linked pricing.
- Groundbreaking
Construction at the new facility near Hazira begins.
- First production
Targeted within 20 months of groundbreaking.
The company also announced a new facility near Hazira, designed to add about 246 tonnes of annual capacity and create roughly 1,200 jobs. Construction begins next quarter, and first production is targeted within 20 months. The plant will be built to meet European environmental standards.
Expert commentary
“Visibility is worth more than growth. We can plan investments when we can see 14 months ahead.”
“The data is clear on direction and less clear on pace. I would plan for slower and be pleasantly surprised.”
“Smaller firms are not at a disadvantage on quality; they are at a disadvantage on paperwork and finance.”
Risks and analyst view
A new long-term agreement with Hindalco Industries anchors a portion of the expansion. The deal covers multi-year supply at index-linked pricing, with volume commitments that provide a floor, and includes a joint development programme for higher-specification products with better margins.
What it means for you
Order visibility and a manageable balance sheet support the story; track execution on the new plant and margin pass-through.
Expansion will lift procurement; engage early on qualification for the new lines.
Longer-term agreements offer price stability in exchange for volume commitments; compare index-linked terms carefully.
About 1,200 direct roles and a technician academy are planned near Hazira; applications open with the state skills portal.
Companies and leaders in this story
Frequently asked questions
Sources
- Directorate General of Foreign Trade: Export-import policy and public notices
- Company filings and earnings calls: Disclosures on order books and capex
- IGEN Intelligence database: Proprietary tracker of announced projects
- Industry association surveys: Member-level compliance and sentiment data
Mock content for demonstration. Names, figures and quotes are illustrative and not real reporting.
